|
1
|
Corless CL, Barnett CM and Heinrich MC:
Gastrointestinal stromal tumours: origin and molecular oncology.
Nat Rev Cancer. 11:865–878. 2011.PubMed/NCBI
|
|
2
|
Rubin BP, Heinrich MC and Corless CL:
Gastrointestinal stromal tumour. Lancet. 369:1731–1741. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Downs-Kelly E and Rubin BP:
Gastrointestinal stromal tumors: molecular mechanisms and targeted
therapies. Patholog Res Int. 2011:7085962011.PubMed/NCBI
|
|
4
|
Blay JY: A decade of tyrosine kinase
inhibitor therapy: historical and current perspectives on targeted
therapy for GIST. Cancer Treat Rev. 37:373–384. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rubin BP: Bioinformatic mining of gene
expression datasets identifies ETV1 as a critical regulator of
oncogenesis in gastrointestinal stromal tumors. Cancer Cell.
18:407–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen Y, Zou H, Yang LY, Li Y, Wang L, Hao
Y and Yang JL: ER81-shRNA inhibits growth of triple-negative human
breast cancer cell line MDA-MB-231 in vivo and in vitro. Asian Pac
J Cancer Prev. 13:2385–2392. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shin S, Bosc DG, Ingle JN, Spelsberg TC
and Janknecht R: Rcl is a novel ETV1/ER81 target gene upregulated
in breast tumors. J Cell Biochem. 105:866–874. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baena E, Shao Z, Linn DE, et al: ETV1
directs androgen metabolism and confers aggressive prostate cancer
in targeted mice and patients. Genes Dev. 27:683–698. 2013.
View Article : Google Scholar
|
|
9
|
Hollenhorst PC, Ferris MW, Hull MA, Chae
H, Kim S and Graves BJ: Oncogenic ETS proteins mimic activated
RAS/MAPK signaling in prostate cells. Genes Dev. 25:2147–2157.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jané-Valbuena J, Widlund HR, Perner S, et
al: An oncogenic role for ETV1 in melanoma. Cancer Res.
70:2075–2084. 2010.
|
|
11
|
Oh S, Shin S and Janknecht R: ETV1, 4 and
5: an oncogenic subfamily of ETS transcription factors. Biochim
Biophys Acta. 1826:1–12. 2012.PubMed/NCBI
|
|
12
|
Chi P, Chen Y, Zhang L, et al: ETV1 is a
lineage survival factor that cooperates with KIT in
gastrointestinal stromal tumours. Nature. 467:849–853. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Duensing A, Medeiros F, McConarty B, et
al: Mechanisms of oncogenic KIT signal transduction in primary
gastrointestinal stromal tumors (GISTs). Oncogene. 23:3999–4006.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Duensing S and Duensing A: Targeted
therapies of gastrointestinal stromal tumors (GIST) - the next
frontiers. Biochem Pharmacol. 80:575–583. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nelson WJ and Nusse R: Convergence of Wnt,
β-catenin, and cadherin pathways. Science. 303:1483–1487. 2004.
|
|
16
|
Pal M, Koul S and Koul HK: The
transcription factor sterile alpha motif (SAM) pointed
domain-containing ETS transcription factor (SPDEF) is required for
E-cadherin expression in prostate cancer cells. J Biol Chem.
288:12222–12231. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Heinrich MC and Corless CL: Cancer:
oncogenes in context. Nature. 467:796–797. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim EK and Choi EJ: Pathological roles of
MAPK signaling pathways in human diseases. Biochim Biophys Acta.
1802:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schoppmann SF, Beer A, Nirtl N,
Ba-Ssalamah A, Brodowicz T, Streubel B and Birner P: Downregulation
of phosphatidylethanolamine binding protein 1 associates with
clinical risk factors in gastrointestinal stromal tumors, but not
with activation of the RAF-1-MEK-ETV1 pathway. Cancer Lett.
335:26–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gulmann C, Sheehan KM, Conroy RM, et al:
Quantitative cell signalling analysis reveals down-regulation of
MAPK pathway activation in colorectal cancer. J Pathol.
218:514–519. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Braig M, Lee S, Loddenkemper C, et al:
Oncogene-induced senescence as an initial barrier in lymphoma
development. Nature. 436:660–665. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu PK, Hong SK, Veeranki S, Karkhanis M,
Starenki D, Plaza JA and Park JI: A mortalin/HSPA9-mediated switch
in tumor-suppressive signaling of Raf/MEK/extracellular
signal-regulated kinase. Mol Cell Biol. 33:4051–4067. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mooi WJ and Peeper DS: Oncogene-induced
cell senescence - halting on the road to cancer. N Engl J Med.
355:1037–1046. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Klonisch T, Wiechec E, Hombach-Klonisch S,
Ande SR, Wesselborg S, Schulze-Osthoff K and Los M: Cancer stem
cell markers in common cancers - therapeutic implications. Trends
Mol Med. 14:450–460. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ghavami S, Hashemi M, Ande SR, et al:
Apoptosis and cancer: mutations within caspase genes. J Med Genet.
46:497–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu J, Cui H, Peng X, et al: Dietary high
fluorine induces apoptosis and alters Bcl-2, Bax, and caspase-3
protein expression in the cecal tonsil lymphocytes of broilers.
Biol Trace Elem Res. 52:25–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Steinert DM, Oyarzo M, Wang X, et al:
Expression of Bcl-2 in gastrointestinal stromal tumors: correlation
with progression-free survival in 81 patients treated with imatinib
mesylate. Cancer. 106:1617–1623. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Q and Kou YW: Study of the
expressions of p53 and bcl-2 genes, the telomerase activity and
apoptosis in GIST patients. World J Gastroenterol. 13:2626–2628.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nogueira V, Park Y, Chen CC, et al: Akt
determines replicative senescence and oxidative or oncogenic
premature senescence and sensitizes cells to oxidative apoptosis.
Cancer Cell. 14:458–470. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Seki E, Brenner DA and Karin M: A liver
full of JNK: signaling in regulation of cell function and disease
pathogenesis, and clinical approaches. Gastroenterology.
143:307–320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Corazza N, Jakob S, Schaer C, et al: TRAIL
receptor-mediated JNK activation and Bim phosphorylation critically
regulate Fas-mediated liver damage and lethality. J Clin Invest.
116:2493–2499. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013.PubMed/NCBI
|
|
33
|
Birner P, Beer A, Vinatzer U, et al:
MAPKAP kinase 2 overexpression influences prognosis in
gastrointestinal stromal tumors and associates with copy number
variations on chromosome 1 and expression of p38 MAP kinase and
ETV1. Clin Cancer Res. 18:1879–1887. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kubota D, Yoshida A, Tsuda H, et al: Gene
expression network analysis of ETV1 reveals KCTD10 as a novel
prognostic biomarker in gastrointestinal stromal tumor. PLoS One.
8:e738962013. View Article : Google Scholar : PubMed/NCBI
|
